New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | all day >>
16:09 EDTZLTQZELTIQ sees FY15 revenue $230M-$235M, consensus $223.98M
Subscribe for More Information
16:08 EDTSWHCSmith & Wesson reports Q3 adjusted EPS 20c, consensus 11c
Reports Q3 revenue $130.6M, consensus $123.32M.
16:08 EDTREGIRenewable Energy reports Q4 EPS $1.61, may not compare to consensus (30c)
Subscribe for More Information
16:08 EDTBOBEBob Evans reports Q3 EPS 60c, consensus 70c
Subscribe for More Information
16:08 EDTAMRNAmarin says REDUCE-IT continues as centerpiece of R&D efforts
Amarin stated: "The REDUCE-IT cardiovascular outcomes study continues to be the centerpiece of Amarin's on-going R&D efforts. This is the first prospective double-blinded cardiovascular outcomes study of any drug in a population of patients who, despite stable statin therapy, have elevated triglyceride levels. Unlike outcomes studies for many drugs that are designed to validate a currently approved drug indication, based on the results of REDUCE-IT, we plan to seek additional indicated uses for Vascepa that include and extend beyond the populations studied in the MARINE and ANCHOR trials. These additional indications would potentially address tens of millions of patients in the United States and worldwide with elevated triglyceride levels representing an opportunity comparable in size to cholesterol management therapy. In the REDUCE-IT study, we seek to demonstrate benefit by augmenting, not replacing, statin therapy...Thus far the pooled, blinded event rate in the REDUCE-IT study is tracking to our expectations for the 60% interim look by the independent DMC to occur during 2016. Based on the efficacy and safety results at the interim look, the DMC could recommend to the independent Steering Committee and to Amarin to continue or stop the study. If the study is stopped based on overwhelming efficacy results, Amarin intends at that time to progress towards seeking approval for an expanded indication for Vascepa based on such results. Amarin is blinded to the results of the REDUCE-IT study and is planning for REDUCE-IT to continue until attainment of 100% of the 1,612 primary events which is estimated to be in 2017 with results anticipated to be published in 2018."
16:07 EDTZLTQZELTIQ reports Q4 EPS 3c, consensus 1c
Subscribe for More Information
16:07 EDTTRIVTriVascular sees FY15 revenue $45M-$49M, consensus $47.6M
Subscribe for More Information
16:07 EDTFOLDAmicus says on track for mid-year marketing application in Europe
The company said, "We remain on track for a mid-year marketing application in Europe for migalastat monotherapy for Fabry disease and we look forward to an upcoming meeting with the FDA to discuss a path forward for an NDA submission for migalastat monotherapy in the United States. We continue to believe firmly that the totality of the data with this important new precision medicine-based therapy should be available to Fabry patients in the U.S. as soon as possible. Finally, advancing our next-generation enzyme replacement therapy for people living with Pompe disease is a key priority and that important program remains on track. Indeed, a busy and important set of activities are ahead for the Amicus team this year. We hope that success in these endeavors will enhance the lives of many people living with Fabry and Pompe diseases."
16:07 EDTTRIVTriVascular reports Q4 EPS (72c), consensus (65c)
Subscribe for More Information
16:06 EDTAMRNAmarin says FDA has not provided timeline for action on ANCHOR sNDA
Subscribe for More Information
16:06 EDTOSHCOcean Shore Holding approves 130,000 repurchase program
Ocean Shore Holding approved the repurchase of up to 130,000 shares of the Company's outstanding common stock, which is approximately 2% of outstanding shares. The Company completed its previously announced stock repurchase program for the purchase of 130,000 shares at an average cost of $14.34 per share.
16:06 EDTFOLDAmicus Therapeutics reports Q4 EPS (24c), consenus (18c)
Subscribe for More Information
16:05 EDTRCPTReceptos sees moving forward with Phase 3 program in ulcerative colitis
Subscribe for More Information
16:05 EDTNPTNNeoPhotonics sees Q1 non-GAAP EPS 9c, consensus (12c)
Sees Q1 revenue $75M-$81M, consensus $73.96M. The Non-GAAP outlook for the Q1 excludes the expected amortization of intangibles and other assets of approximately $1.8M, and the anticipated impact of stock-based compensation of approximately $2.0M, of which $300,000 is estimated for cost of goods sold.
16:04 EDTTIVOTiVo reports Q4 service, technology revenue $91.7M, consensus $89.85M
Subscribe for More Information
16:04 EDTWES, WGPWestern Gas Partners sees 2015 distribution growth no less than 15%
Subscribe for More Information
16:04 EDTACASAmerican Capital appoints John Scheurer as Chief Investment Officer
American Capital announced that John Scheurer joined the company on March 1, as Managing Director and Chief Investment Officer in the Commercial Real Estate Group. Scheurer will be responsible for developing a commercial real estate platform, alongside American Capital Managing Director Doug Cooper and the existing Commercial Real Estate Group. American Capital may fund its commercial real estate investments by incubating a commercial mortgage real estate investment trust, which it would manage.
16:04 EDTRCPTReceptos reports Q4 EPS ($1.32), consensus ($1.19)
Subscribe for More Information
16:04 EDTTIVOTiVo sees Q1 service, technology revenue $90M-$92M, consensus $92.33M
Subscribe for More Information
16:04 EDTGMCR, COTKeurig Green Mountain and DS Services announce partnership
Keurig Green Mountain (GMCR) and DS Services of America, a subsidiary of Cott (COT) and a leading bottled water, coffee and tea direct-to-consumer services provide announced a multi-year agreement to offer DS Services' Javarama coffee in K-Cup packs for use in Keurig hot brewing systems. "We're excited to expand our Keurig Authorized Distributor relationship with DS Services by offering their popular Javarama brand to customers in K-Cup packs," said John Whoriskey, President, U.S. Sales & Marketing for Keurig. "With over 400 varieties from 60 brands already available in the Keurig hot system, Javarama coffee will be a welcome addition to the Keurig family
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use